Related Experiment Video
Updated: Mar 10, 2026
06:54
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
3.4K
Cerebrolysin for acute ischaemic stroke
Liliya Eugenevna Ziganshina1, Tatyana Abakumova1, Ludivine Vernay2
1Department of Basic and Clinical Pharmacology, Kazan (Volga region) Federal University, 18 Kremlevskaya Street, 420008, 14-15 Malaya Krasnaya Street, 420015, Kazan, Tatarstan, Russian Federation.
The Cochrane Database of Systematic Reviews
|December 6, 2016
Summary
Cerebrolysin (a mixture of peptides and amino acids) showed no clinical benefits for acute ischemic stroke treatment. Moderate-quality evidence suggests it may increase the risk of serious adverse events in stroke patients.
Area of Science:
- Neurology
- Pharmacology
Background:
- Cerebrolysin, a pig brain-derived peptide mixture, is used for acute ischemic stroke in several countries.
- It is believed to possess neuroprotective and neurotrophic properties.
Purpose of the Study:
- To evaluate the efficacy and safety of Cerebrolysin in acute ischemic stroke patients.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs).
- Searched multiple databases including Cochrane, MEDLINE, Embase, and Russian databases up to May 2016.
- Included six RCTs with 1501 participants comparing Cerebrolysin with placebo or no treatment.
Main Results:
- No significant difference in all-cause mortality between Cerebrolysin and placebo groups (RR 0.91, 95% CI 0.61 to 1.35).
- Moderate-quality evidence indicates a potential increase in serious adverse events with Cerebrolysin use (RR 1.37, 90% CI 1.01 to 1.86).
- No difference observed in the total number of adverse events.
Conclusions:
- Current evidence does not support the clinical benefits of Cerebrolysin for acute ischemic stroke.
- Cerebrolysin use in acute ischemic stroke may be associated with an increased risk of serious adverse events.
